| 1 |
NCT02158052 |
Recruiting |
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease |
- Multiple Myeloma
- Amyloidosis
|
- Drug: Tacrolimus
- Drug: Anti-thymocyte globulin
- Procedure: Kidney transplant
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint is the renal allograft rejection rate at 6 months post-transplant.
- Assess anti-tumor response rates in patients with hematologic malignancies
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02158052 |
KdBMT-2 |
|
February 2015 |
February 2020 |
February 2021 |
June 6, 2014 |
March 16, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 2 |
NCT03413800 |
Recruiting |
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant |
- Relapsed Hematologic Malignancy
- Multiple Myeloma
|
- Drug: Lenalidomide-Dexamethasone-DLI
|
Interventional
|
Phase 2 |
- Ciusss de L'Est de l'Île de Montréal
- Celgene
- Centre de Commercialisation en Immunothérapie du Cancer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of Len-Dex-DLI in patients with relapsed myeloma measured by progression-free survival
- Incidence of grade ≥III non hematologic toxicity and incidence of grade ≥IV hematologic toxicity
- Incidence of acute GVHD
- (and 10 more...)
|
15 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03413800 |
HMR003 |
|
February 12, 2018 |
January 29, 2021 |
January 29, 2023 |
January 29, 2018 |
January 31, 2019 |
|
- CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montréal, Quebec, Canada
|
|
| 3 |
NCT02885623 |
Recruiting |
Role of CX3CR1-expressing Cells in Hematologic Malignancy |
- CX3CR1 Protein
- Diffuse Large B Cell Lymphoma
- Multiple Myeloma
|
|
Observational
|
|
- Saint Vincent's Hospital, Korea
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- progression free survival
- overall survival
- Death
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02885623 |
001 |
|
August 2016 |
August 2019 |
August 2021 |
August 31, 2016 |
October 11, 2017 |
|
- The Catholic University of Korea, St.Vincent's hospital
Suwon-si, Gyeonggi-do, Korea, Republic of
|
|
| 4 |
NCT03590652 |
Recruiting |
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma |
- Relapsed/Refractory Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Pomalidomide
- Drug: Dexamethasone
- Drug: Daratumumab
|
Interventional
|
Phase 2 |
- Caitlin Costello, MD
- Celgene
- Takeda
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Clinical benefit rate
- (and 5 more...)
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT03590652 |
180638 |
|
October 17, 2018 |
October 1, 2020 |
October 1, 2021 |
July 18, 2018 |
January 15, 2019 |
|
- UCSD Moores Cancer Center
La Jolla, California, United States
|
|
| 5 |
NCT02918695 |
Recruiting |
Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients |
- Multiple Myeloma
- Hematologic Diseases
|
|
Observational
|
|
- Universitaire Ziekenhuizen Leuven
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comparison of the geriatric categorization (fit versus frail) by standard clinical assessment versus by geriatric scoring.
- Comparison of the geriatric categorization (fit versus frail) by CGA versus by IMWG scoring
- Change in geriatric categorization (fit versus frail) by CGA from baseline to 3 months of anti-myeloma therapy.
- (and 10 more...)
|
200 |
All |
70 Years and older (Older Adult) |
NCT02918695 |
NA-NI-MM-PI-006760 |
COMPASS |
April 7, 2017 |
July 2019 |
July 2019 |
September 29, 2016 |
October 12, 2018 |
|
- ZNA Antwerpen
Antwerpen, Belgium - Centre Hospitalier EpiCURA
Baudour, Belgium - Imelda Ziekenhuis
Bonheiden, Belgium - (and 18 more...)
|
|
| 6 |
NCT03316209 |
Recruiting |
Identification of Occupational Exposures in Acute Hematologic Malignancy |
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
|
|
Observational
|
|
- Centre Hospitalier Intercommunal Creteil
- ANSES
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- ability of the questionnaire to identify occupational carcinogenic exposures
- Acceptability of the questionnaire by patients
- Determination of the number of subjects recorded as suffering of an occupational disease
- (and 2 more...)
|
300 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT03316209 |
RHELYPRO |
RHELYPRO |
April 25, 2017 |
March 2020 |
September 2020 |
October 20, 2017 |
February 6, 2019 |
|
- CHU Bordeaux
Bordeaux, France - CHU H. Mondor
Créteil, France - Service de pathologie professionelle
Créteil, France - (and 3 more...)
|
|
| 7 |
NCT03490084 |
Not yet recruiting |
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma |
|
- Other: Association of day hospitalization with hospital-at-home
- Other: Day hospitalization exclusively
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in Quality of life using questionnaires EORTC QLQ-30
- Change in Quality of life using questionnaires EORTC QLQ-MY20
- Survival
- (and 5 more...)
|
300 |
All |
65 Years and older (Older Adult) |
NCT03490084 |
P_PREPS 16-596 |
PAMM-HAD1 |
January 2019 |
September 2021 |
September 2021 |
April 6, 2018 |
October 16, 2018 |
|
- HAD
Paris, Île-de-France, France
|
|
| 8 |
NCT03829020 |
Not yet recruiting
New |
Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Drug: Bortezomib
- Drug: Metformin Hydrochloride
- Drug: Nelfinavir Mesylate
|
Interventional
|
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of the combination of metformin and nelfinavir
- Incidence of adverse events
- Hematologic response rate
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03829020 |
MC1811
NCI-2019-00466
P30CA015083 |
|
March 1, 2019 |
August 21, 2021 |
August 21, 2021 |
February 4, 2019 |
February 4, 2019 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 9 |
NCT03525678 |
Recruiting |
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody |
|
- Drug: GSK2857916 frozen
- Drug: GSK2857916 lyophilized
- Other: NEI-VFQ-25 Questionnaire
- (and 3 more...)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Clinical benefit rate (CBR)
- Duration of response (DoR)
- (and 22 more...)
|
155 |
All |
18 Years and older (Adult, Older Adult) |
NCT03525678 |
205678 |
|
June 18, 2018 |
June 30, 2019 |
June 30, 2020 |
May 16, 2018 |
October 12, 2018 |
|
- GSK Investigational Site
Atlanta, Georgia, United States - GSK Investigational Site
Atlanta, Georgia, United States - GSK Investigational Site
Chicago, Illinois, United States - (and 49 more...)
|
|
| 10 |
NCT01592370 |
Recruiting |
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma |
- Non-Hodgkin's Lymphoma
- Hodgkin Lymphoma
- Multiple Myeloma
|
- Biological: Nivolumab
- Biological: Ipilimumab
- Biological: Lirilumab
- (and 3 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Bristol-Myers Squibb
- Janssen, LP
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of Nivolumab alone and in combination as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities, and laboratory test abnormalities
- Maximum observed serum concentration (Cmax)
- Serum concentration achieved at the end of dosing interval (trough concentration, all participants) [Cmin]
- (and 12 more...)
|
375 |
All |
18 Years and older (Adult, Older Adult) |
NCT01592370 |
CA209-039
2018-001030-17 |
|
June 27, 2012 |
June 14, 2020 |
June 15, 2020 |
May 7, 2012 |
January 15, 2019 |
|
- Local Institution
Little Rock, Arkansas, United States - Local Institution
Fresno, California, United States - Local Institution
Long Beach, California, United States - (and 44 more...)
|
|
| 11 |
NCT03224507 |
Recruiting |
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma |
|
- Drug: KRdD followed by auto-HCT
- Drug: KRdD only
|
Interventional
|
Phase 2 |
- University of Alabama at Birmingham
- Amgen
- Janssen Scientific Affairs, LLC
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients with MRD(-) remissions at the completion of consolidation therapy
- Serious adverse events (SAEs) from the KRdD treatment
- Percentage of patients with MRD(-) status at the completion of induction therapy
- (and 5 more...)
|
82 |
All |
18 Years and older (Adult, Older Adult) |
NCT03224507 |
F170525008 (UAB 1735) |
MASTER |
March 14, 2018 |
April 1, 2021 |
April 1, 2023 |
July 21, 2017 |
January 14, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Wisconsin, school of medicine and public health
Madison, Wisconsin, United States
|
|
| 12 |
NCT03127761 |
Recruiting |
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma |
|
- Other: Allogeneic Hematopoietic Stem Cell Transplant
|
Observational
|
|
- Center for International Blood and Marrow Transplant Research
- National Marrow Donor Program
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Compare five-year survival
- Progression-free survival (PFS)
- Relapse or progression
- (and 3 more...)
|
544 |
All |
Child, Adult, Older Adult |
NCT03127761 |
17-CMS-MM |
|
July 25, 2017 |
May 2027 |
April 2028 |
April 25, 2017 |
September 13, 2017 |
|
- Center for International Blood and Marrow Transplant Research
Minneapolis, Minnesota, United States
|
|
| 13 |
NCT03762291 |
Not yet recruiting |
Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine |
|
- Biological: CVD908ssb-TXSVN
|
Interventional
|
Phase 1 |
- Baylor College of Medicine
- The Methodist Hospital System
- Texas Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with dose limiting toxicity (DLT) by CTCAE 4.X.
- Overall response rate according to the modified International Myeloma Working Group (IMWG) Uniform Response criteria.
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03762291 |
H-42712 MAPSS |
MAPSS |
January 1, 2019 |
January 1, 2022 |
November 1, 2026 |
December 3, 2018 |
December 3, 2018 |
|
|
|
| 14 |
NCT03746652 |
Not yet recruiting |
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Daratumumab, Ixazomib, Dexamethasone
|
Interventional
|
Phase 2 |
- Hellenic Society of Hematology
- Janssen Pharmaceutica NV
- Takeda Pharmaceuticals Company Ltd.
- Hellenic Society of Hematology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Evaluation of the hematologic and non-hematologic toxicity profile of the combination.
- Duration of response (DOR)
- (and 6 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03746652 |
ΕΑΕ-2018/ΜΜ03 |
DARIA |
December 2018 |
December 2021 |
December 2021 |
November 20, 2018 |
November 22, 2018 |
|
- General Hospital of Athens "Alexandra"
Athens, Attica, Greece
|
|
| 15 |
NCT01119066 |
Recruiting |
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies |
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Multiple Myeloma
|
- Radiation: total body irradiation
- Drug: Thiotepa
- Drug: Cyclophosphamide
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the incidence of durable hematopoietic engraftment for T-cell depleted transplants fractionated by the CliniMACS system administered after each of the four disease targeted cytoreduction regimens.
- To assess the incidence and severity of acute and chronic GVHD following T-cell depleted, CD34+ progenitor cell enriched transplants fractionated by the CliniMACS system.
- To assess the incidence of non-relapse mortality (transplant-related mortality) following each cytoreduction regimen and a transplant fractionated by the CliniMACS system.
- (and 3 more...)
|
400 |
All |
up to 69 Years (Child, Adult, Older Adult) |
NCT01119066 |
10-050 |
|
May 2010 |
May 2019 |
May 2019 |
May 7, 2010 |
October 23, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 16 |
NCT03477643 |
Recruiting |
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) |
- Relapsed and Refractory Multiple Myeloma
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Level of compliance at PETHEMA centres in Spain with the clinical practice guidelines proposed by the Spanish Myeloma Group for the treatment of relapsed and refractory MM with POMCIDEX.
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03477643 |
GEM-POMCIDEX |
|
April 27, 2018 |
March 13, 2019 |
December 13, 2019 |
March 26, 2018 |
February 1, 2019 |
|
- Hospital de Sant Joan de Déu
Barcelona, Spain - Hospital Donostia-Donostia Ospitalea
Donostia, Spain - Hospital Universitario Virgen de Las Nieves
Granada, Spain - (and 23 more...)
|
|
| 17 |
NCT03440411 |
Recruiting |
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment |
|
- Drug: Pomalidomide
- Drug: Cyclophosphamide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Fondazione Neoplasie Sangue Onlus
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Time to clinical progression
- Progression free-survival (PFS)
- (and 3 more...)
|
260 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03440411 |
PO-CL-MM-PI-003887 |
PO-3887 |
February 18, 2016 |
February 18, 2021 |
February 18, 2023 |
February 21, 2018 |
February 21, 2018 |
|
- FO.NE.SA.Onlus
Torino, Italy
|
|
| 18 |
NCT03475628 |
Recruiting |
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma |
|
|
Interventional
|
Phase 2 |
- Hellenic Society of Hematology
- Janssen Pharmaceuticals
- Hellenic Society of Hematology
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- changes in bone resorption marker, C-telopeptide of collagen type 1 (CTX), after 4 months of daratumumab monotherapy
- changes in bone resorption marker, namely, tartrate-resistant acid phosphatase-5b (TRACP-5b) after 4 months of daratumumab monotherapy
- Changes in bone formation marker, bALP.
- (and 19 more...)
|
57 |
All |
18 Years and older (Adult, Older Adult) |
NCT03475628 |
EAE-2017/MM01 |
REBUILD |
February 21, 2018 |
June 20, 2019 |
February 20, 2020 |
March 23, 2018 |
March 23, 2018 |
|
- General Hospital of Athens "Alexandra"
Athens, Attica, Greece
|
|
| 19 |
NCT03641456 |
Not yet recruiting |
VRD as Induction Followed by IR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma |
- Myeloma
- Newly Diagnosed
- High Risk
|
- Drug: bortezomib
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Ixazomib
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Very good partial response or better by International Myeloma Working Group criteria
- progression free survival
- overall survival
- (and 3 more...)
|
50 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03641456 |
MM-2018 |
|
January 10, 2019 |
September 30, 2020 |
September 30, 2022 |
August 22, 2018 |
January 21, 2019 |
|
- Sun Yat-sen University Cancer Center
GuangZhou, Guangdong, China
|
|
| 20 |
NCT02576496 |
Recruiting |
Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
- Hematological Malignancies
- Multiple Myeloma
- Hodgkin's Lymphoma
- (and 3 more...)
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Classification of each stage 2 cohort as to interest or no interest based upon overall response rate
- Overall response rate
- Clinical benefit rate by cohort
- (and 7 more...)
|
111 |
All |
18 Years and older (Adult, Older Adult) |
NCT02576496 |
EDO-S101-1001 |
|
March 2016 |
December 2020 |
May 2021 |
October 15, 2015 |
January 10, 2019 |
|
- Mayo Clinic
Phoenix, Arizona, United States - Mayo Clinic Cancer Center
Jacksonville, Florida, United States - Mayo Clinic Cancer Center
Rochester, Minnesota, United States - (and 13 more...)
|
|
| 21 |
NCT01250808 |
Available |
Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy |
|
- Drug: Bortezomib/Dexamethasone/Melphalan
|
Expanded Access
|
|
|
Other |
|
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT01250808 |
2008ZX09312-026 |
|
|
|
|
December 1, 2010 |
December 1, 2010 |
|
- Institute of Hematology,Peking University
Peking, China
|
|
| 22 |
NCT03187223 |
Recruiting |
Bendamustine and Melphalan in Myeloma |
|
- Drug: Melphalan
- Drug: Bendamustine
|
Interventional
|
Phase 2 |
- University Hospital Inselspital, Berne
- Mundipharma Medical Company
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Remission rate
- Adverse events
- Hematologic engraftment after high-dose chemotherapy
- (and 2 more...)
|
120 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03187223 |
BEB-2 Trial |
BEB-2 |
July 20, 2017 |
October 2020 |
March 2021 |
June 14, 2017 |
December 3, 2018 |
|
- Department for Medical Oncology University Hospital/Inselspital
Berne, Switzerland
|
|
| 23 |
NCT03450057 |
Recruiting |
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment |
|
|
Interventional
|
Phase 2 |
- Hellenic Society of Hematology
- Janssen Pharmaceuticals
- Hellenic Society of Hematology
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The evaluation of progression free survival (PFS) in subjects with relapsed or refractory multiple myeloma and renal impairment treated with daratumumab and dexamethasone
- Overall response rate (ORR)
- Renal response rate (RRR)
- (and 4 more...)
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT03450057 |
EAE-2017/MM02 |
|
February 15, 2018 |
April 2020 |
August 2020 |
March 1, 2018 |
March 1, 2018 |
|
- General Hospital of Athens "Alexandra"
Athens, Attica, Greece
|
|
| 24 |
NCT02439476 |
Recruiting |
Non-interventional Study on Salvage Auto in Relapsed Myeloma |
- Relapsed Multiple Myeloma
|
|
Observational
|
|
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Feasibility to collect at least 2x10e6/kg CD34+ peripheral blood cell stem cells
- Engraftment after ASCT (neutrophil and platelets recovery)
- Time to disease progression
- (and 4 more...)
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02439476 |
IFM-2015-03 |
IFM-2015-03 |
August 8, 2016 |
June 2019 |
June 2020 |
May 8, 2015 |
January 9, 2019 |
|
- Hématologie Clinique, Hôpital Saint Antoine
Paris, France
|
|
| 25 |
NCT03225417 |
Recruiting |
Ixazomib in Combination With Sirolimus and Tacrolimus in the Prophylaxis of Chronic Graft-versus-host Disease. |
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Tacrolimus
- Drug: Sirolimus
|
Interventional
|
Phase 1
Phase 2 |
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To identify the optimal dose and evaluate ixazomib tolerance used after transplantation for the phase I study
- Efficacy of ixazomib for phase II study
- Event free survival
- (and 3 more...)
|
154 |
All |
18 Years and older (Adult, Older Adult) |
NCT03225417 |
X16082 |
|
May 16, 2017 |
June 27, 2020 |
May 27, 2023 |
July 21, 2017 |
July 21, 2017 |
|
- ICO- Hospital Germans Trias i Pujol
Badalona, Spain - Hospital Clinic de Barcelona
Barcelona, Spain - Hospital de la Santa Creu I Sant Pau
Barcelona, Spain - (and 4 more...)
|
|
| 26 |
NCT03759093 |
Not yet recruiting |
CURATE.AI Optimized Modulation for Multiple Myeloma |
|
- Drug: Velcade
- Drug: Cyclophosphamide
- Drug: Dexamethasone
- Other: CURATE.AI-Guided dosage modulation
|
Interventional
|
Phase 2
Phase 3 |
- National University Hospital, Singapore
- National University, Singapore
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
|
20 |
All |
21 Years to 99 Years (Adult, Older Adult) |
NCT03759093 |
2015/00280 |
|
January 1, 2019 |
January 1, 2021 |
January 1, 2021 |
November 29, 2018 |
November 29, 2018 |
|
- National University Hospital
Singapore, Singapore
|
|
| 27 |
NCT03773107 |
Recruiting |
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma |
|
- Drug: Carfilzomib
- Drug: Ruxolitinib
- Drug: Dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Saad Z. Usmani, MD
- Incyte Corporation
- Multiple Myeloma Research Consortium
- (and 2 more...)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
|
48 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03773107 |
LCI-HEM-MYE-CRD-004
00031040 |
|
January 3, 2019 |
December 31, 2020 |
December 31, 2025 |
December 12, 2018 |
January 10, 2019 |
|
- Levine Cancer Institute
Charlotte, North Carolina, United States
|
|
| 28 |
NCT03711110 |
Not yet recruiting |
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) |
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Multiple Myeloma)
- Elderly
- Antineoplastic Agents
- Cardiotoxicity
|
- Other: Intensive cardiovascular monitoring
- Other: No intervention
|
Interventional
|
Not Applicable |
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
- Instituto de Investigación Biomédica de Salamanca
- Instituto de Salud Carlos III
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- All-cause mortality
- Oncological mortality
- Cardiovascular mortality
- (and 4 more...)
|
514 |
All |
65 Years and older (Older Adult) |
NCT03711110 |
CARTIER |
CARTIER |
March 30, 2019 |
October 30, 2024 |
November 30, 2024 |
October 18, 2018 |
February 6, 2019 |
|
- Hospital Clínico Universitario de Santiago de Compostela
Santiago De Compostela, A Coruña, Spain - Hospital de Galdakao-Usansolo
Galdakao, Vizcaya, Spain - Hospital Universitario Vall d´Hebron
Barcelona, Spain - (and 11 more...)
|
|
| 29 |
NCT03353545 |
Recruiting |
A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in RRMM Patients Under Real-Life Conditions |
- Relapse/Refractory Multiple Myeloma
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Effectiveness of Pom/LoDex in terms of median PFS
- Response to Pom/LoDex treatment in terms of ORR
- Response to Pom/LoDex treatment in terms of CBR
- (and 6 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03353545 |
NIS-GEN-POM-001 |
POWERFUL |
November 16, 2017 |
February 2020 |
February 2020 |
November 27, 2017 |
September 3, 2018 |
|
- Ag.Andreas General Hospital
Patra, Greece
|
|
| 30 |
NCT03218683 |
Recruiting |
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. |
- Relapsed or Refractory Hematologic Malignancies
- Non-Hodgkin Lymphoma
- Richter Syndrome
- (and 4 more...)
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Adverse Events
- Dose limiting toxicities
- maximum tolerated dose
- (and 5 more...)
|
48 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03218683 |
D6910C00001 |
|
August 2, 2017 |
October 23, 2019 |
October 23, 2019 |
July 14, 2017 |
January 21, 2019 |
|
- Research Site
Orange, California, United States - Research Site
Aurora, Colorado, United States - Research Site
Washington, District of Columbia, United States - (and 10 more...)
|
|
| 31 |
NCT03361306 |
Recruiting |
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M |
|
|
Interventional
|
Phase 2 |
- Saad Z. Usmani, MD
- Bristol-Myers Squibb
- Carolinas Healthcare System
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival at 2 years
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03361306 |
LCI-HEM-MYE-CRD-002 |
|
December 15, 2017 |
December 31, 2020 |
December 31, 2020 |
December 4, 2017 |
November 16, 2018 |
|
- Levine Cancer Institute (Main)
Charlotte, North Carolina, United States
|
|
| 32 |
NCT03091933 |
Recruiting |
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) |
- Hematologic Cancer
- Relapse Leukemia
- Relapsed Adult ALL
- (and 6 more...)
|
|
Interventional
|
Phase 1
Phase 2 |
- Ciusss de L'Est de l'Île de Montréal
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-hematologic toxicity related to GLIDE post injection
- Response of hematologic malignancy (acute leukemia (ALL, AML, biphenotypic), CLL, HL, NHL, MM or MDS) post-injection
- Incidence and severity of acute and chronic graft versus host disease (GvHD)
- (and 5 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03091933 |
CR-MIHA-001 |
GLIDE |
February 6, 2017 |
March 31, 2018 |
March 31, 2019 |
March 27, 2017 |
December 6, 2017 |
|
- CIUSSS d l'Est-de-l'Île-de-Montréal
Montreal, Quebec, Canada
|
|
| 33 |
NCT01028716 |
Recruiting |
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
- Acute Biphenotypic Leukemia
- Acute Erythroid Leukemia in Remission
- Acute Leukemia in Remission
- (and 27 more...)
|
- Drug: Cyclophosphamide
- Biological: Filgrastim
- Drug: Fludarabine Phosphate
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cumulative incidence of non-relapse mortality, defined as death without evidence of disease progression
- Incidence of chronic graft versus host disease
- Incidence of grades III/IV acute graft versus host disease
- (and 9 more...)
|
50 |
All |
Child, Adult, Older Adult |
NCT01028716 |
2372.00
NCI-2009-01433
2372
P30CA015704 |
|
February 8, 2010 |
March 1, 2019 |
|
December 9, 2009 |
November 12, 2018 |
|
- VA Puget Sound Health Care System
Seattle, Washington, United States - Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 34 |
NCT02274519 |
Recruiting |
Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma |
- Multiple Myeloma
- Plasma Cell Disorder
|
- Other: Tai Chi
- Other: Education
|
Interventional
|
Not Applicable |
- Mayo Clinic
- Arizona State University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Quality of life
- Time to engraftment
- Rate of febrile neutropenia
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT02274519 |
14-007210 |
|
February 2015 |
September 2018 |
September 2018 |
October 24, 2014 |
October 13, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
|
|
| 35 |
NCT03839459 |
Not yet recruiting
New |
Denosumab for Smoldering Multiple Myeloma |
- Smoldering Multiple Myeloma
|
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of subjects with a downgraded risk of progression of smoldering multiple myeloma if the risk category decreases.
- Proportion of subjects with Skeletal related Events
- Proportion of subjects with disease progression to Multiple Myeloma
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03839459 |
UMMY18121 |
|
March 1, 2019 |
March 1, 2021 |
March 1, 2024 |
February 15, 2019 |
February 15, 2019 |
|
|
|
| 36 |
NCT02892383 |
Recruiting |
Quality of Life the Danish Multiple Myeloma Patients |
- Quality of Life
- Multiple Myeloma
|
|
Observational
|
|
- Odense University Hospital
- Danish Myeloma Study Group
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients.
- Description of changes in QoL over time, based on PROM for the general population of multiple myeloma patients.
- Description of the impact of peripheral neuropathy on QoL in the general population of multiple myeloma patients over time, based on PROM.
- Description of the impact of recalibration response shift for interpretation of data from longitudinal QoL studies using PROM for QoL measurement in the general population of previously untreated multiple myeloma patients.
|
800 |
All |
18 Years to 110 Years (Adult, Older Adult) |
NCT02892383 |
QoL-MM_OUH |
QoL-MM |
February 27, 2017 |
August 1, 2022 |
February 1, 2023 |
September 8, 2016 |
September 18, 2017 |
|
- Sygehus Sønderjylland
Aabenraa, Denmark - Aalborg University Hospital
Aalborg, Denmark - Aarhus University Hospital
Aarhus, Denmark - (and 7 more...)
|
|
| 37 |
NCT03445663 |
Recruiting |
Study Evaluating AMG 424 in Subjects With Multiple Myeloma |
- Relapsed/ Refractory Multiple Myeloma
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0
- Subject incidence of dose limiting toxicities (DLTs)
- Anti-tumor activity
- (and 8 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03445663 |
20160445 |
|
July 31, 2018 |
July 7, 2021 |
July 7, 2021 |
February 26, 2018 |
February 15, 2019 |
|
- Research Site
Winston-Salem, North Carolina, United States - Research Site
Camperdown, New South Wales, Australia - Research Site
Fitzroy, VIC, Victoria, Australia
|
|
| 38 |
NCT03155100 |
Recruiting |
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines |
- Multiple Myeloma in Relapse
|
- Drug: Carfilzomib for Inj 60 milligram (MG)
- Drug: Elotuzumab 400 MG
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Raija Silvennoinen
- Amgen
- Bristol-Myers Squibb
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Severe adverse events
|
40 |
All |
18 Years to 74 Years (Adult, Older Adult) |
NCT03155100 |
NMSG#24/15
2016-001178-13 |
KEd |
August 7, 2017 |
June 21, 2020 |
June 30, 2023 |
May 16, 2017 |
January 8, 2019 |
|
- Helsinki University Central Hospital
Helsinki, Finland - Central Finland Central Hospital
Jyväskylä, Finland - Kymenlaakso Central Hospital
Kotka, Finland - (and 5 more...)
|
|
| 39 |
NCT03733717 |
Recruiting |
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma |
|
- Drug: Isatuximab SAR650984
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of PK: Cmax
- Assessment of PK: tmax
- Assessment of PK: AUC0-168h
- (and 9 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03733717 |
TED15085
U1111-1195-6028 |
|
October 22, 2018 |
September 30, 2020 |
May 2, 2022 |
November 7, 2018 |
November 7, 2018 |
|
- Tianjin Hematology Institution
Tianjin, China
|
|
| 40 |
NCT02286830 |
Recruiting |
Prolonged Protection From Bone Disease in Multiple Myeloma |
|
|
Interventional
|
Phase 4 |
- Thomas Lund
- Odense University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- time to first skeletal related event after randomisations at year two
- Value of serum bone marker ratio (bone resorption / bone formation markers) as predictor of skeletal related related events analysed by time-dependent multiparameter Cox regression analysis.
|
158 |
All |
18 Years and older (Adult, Older Adult) |
NCT02286830 |
NMSG 22/14
2014-001121-32 |
Magnolia |
January 2015 |
January 2021 |
March 2021 |
November 10, 2014 |
October 12, 2017 |
|
- Odense University Hospital
Odense C, Denmark
|
|
| 41 |
NCT01760655 |
Recruiting |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- (and 65 more...)
|
- Drug: Fludarabine phosphate
- Drug: Thiotepa
- Radiation: Total body irradiation
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Overall survival
- Incidence of Regimen Related Toxicity
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT01760655 |
12D.501
2012-67 |
|
December 24, 2012 |
December 2019 |
January 2020 |
January 4, 2013 |
March 6, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 42 |
NCT01137643 |
Recruiting |
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 5 more...)
|
- Other: biologic sample preservation procedure
- Other: cytology specimen collection procedure
|
Observational
|
|
- UNC Lineberger Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies
- Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens
|
15000 |
All |
18 Years to 120 Years (Adult, Older Adult) |
NCT01137643 |
LCCC 0824
P30CA016086
CDR0000674072 |
|
July 2009 |
July 2040 |
July 2040 |
June 4, 2010 |
September 21, 2017 |
|
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 43 |
NCT03439280 |
Recruiting |
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) |
- Relapsed/Refractory
- Multiple Myeloma
|
|
Interventional
|
Phase 1
Phase 2 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Phase 1: Number of Participants Reporting one or more Treatment-emergent Adverse Events (TEAEs)
- Phase 1: Number of Participants with Dose-limiting Toxicities (DLTs)
- Phase 1: Number of Participants with Grade 3 or Higher TEAEs
- (and 22 more...)
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT03439280 |
TAK-079-1501
U1111-1208-3202 |
|
April 26, 2018 |
October 28, 2020 |
October 28, 2020 |
February 20, 2018 |
September 17, 2018 |
|
- City of Hope - Duarte
Duarte, California, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - Mount Sinai Hospital-The Donald H. Ruttenberg Cancer Treatment Center
New York, New York, United States - (and 6 more...)
|
|
| 44 |
NCT03398200 |
Recruiting |
Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma |
|
- Biological: Hyperbaric Oxygen Therapy
- Other: No Hyperbaric Oxygen Therapy
|
Interventional
|
Phase 2 |
- Omar Aljitawi
- University of Rochester
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time from transplant to neutrophil count recovery
- Time from transplant to platelet recovery
- Time from transplant to absolute lymphocyte recovery
- (and 4 more...)
|
100 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03398200 |
70180
UBMT17083 |
|
May 10, 2018 |
May 1, 2020 |
May 1, 2021 |
January 12, 2018 |
May 17, 2018 |
|
- Wilmot Cancer Institute, University of Rochester Medical Center
Rochester, New York, United States
|
|
| 45 |
NCT03242460 |
Recruiting |
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) |
- Relapsed and/or refractorY Multiple Myeloma
|
- Drug: Pomalidomide 4 MG
- Drug: Dexamethasone 20mg
- Drug: Cyclophosphamide 400mg
|
Interventional
|
Phase 2 |
- Kosin University Gospel Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Progression-free Survival (PFS)
- Objective Response Rate (ORR)
- Overall survival (OS)
- Safety evaluations assessed using Common Terminology Criteria for Adverse Events v4.0
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT03242460 |
PORYOU |
PORYOU |
May 12, 2015 |
December 31, 2018 |
December 31, 2019 |
August 8, 2017 |
August 8, 2017 |
|
- Catholic university of korea, Seoul ST. Mary's Hospital.
Seoul, Korea, Republic of
|
|
| 46 |
NCT03622788 |
Not yet recruiting |
Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant |
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia in Remission
- (and 15 more...)
|
- Biological: Anti-Thymocyte Globulin
- Drug: Cyclophosphamide
- Biological: Cytokine-treated Veto Cells
- (and 3 more...)
|
Interventional
|
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Optimal dose of donor-derived cytokine-treated veto cells
- Efficacy of veto cells defined as the patient being alive and engrafted at day 42 post veto cell infusion.
- Incidence of adverse events
- (and 5 more...)
|
48 |
All |
12 Years to 70 Years (Child, Adult, Older Adult) |
NCT03622788 |
2018-0221
NCI-2018-01557
P30CA016672 |
|
December 31, 2018 |
April 1, 2020 |
April 1, 2020 |
August 9, 2018 |
August 9, 2018 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 47 |
NCT03767751 |
Recruiting |
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma |
|
- Biological: Dual Specificity CD38 and bcma CAR-T Cells
|
Interventional
|
Phase 1
Phase 2 |
- Chinese PLA General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Severe/Adverse Events as a Measure of Safety and Tolerability
- MTD of dual specificity CD38 and BCMA CAR-T cells
- Copies numbers of CAR in peripheral blood(PB), bone marrow(BM)and lymph nodes
- (and 3 more...)
|
80 |
All |
12 Years to 70 Years (Child, Adult, Older Adult) |
NCT03767751 |
CHN-PLAGH-BT-037 |
|
December 5, 2018 |
December 5, 2022 |
December 5, 2022 |
December 7, 2018 |
December 7, 2018 |
|
- Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital
Beijing, China
|
|
| 48 |
NCT03836014 |
Not yet recruiting
New |
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Combination Product: Daratumumab/Lenalidomide/Dexamethasone for 24 months
- Combination Product: Daratumumab/Lenalidomide/Dexamethasone until progression
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- Response rate
- overall response rate (ORR)
- (and 4 more...)
|
434 |
All |
18 Years and older (Adult, Older Adult) |
NCT03836014 |
D20180138
2016-002129-12 |
CONFIRM |
March 2019 |
March 2023 |
March 2025 |
February 11, 2019 |
February 11, 2019 |
|
- Saint Antoine Hospital - Hematology Department
Paris, France
|
|
| 49 |
NCT03601624 |
Recruiting |
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans |
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
- Refractory Multiple Myeloma
|
|
Interventional
|
Phase 2 |
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety: Incidence of Treatment - Emergent Adverse Events
- Efficacy as secondary endpoints: progression free survival, overall survival and overall response rate
|
18 |
All |
18 Years and older (Adult, Older Adult) |
NCT03601624 |
ISSSTE-POM-CY-MM-2018 |
MM-POM-2018 |
September 1, 2018 |
December 31, 2018 |
July 30, 2020 |
July 26, 2018 |
November 14, 2018 |
|
- ISSSTE
Ciudad de Mexico, Mexico
|
|
| 50 |
NCT03832127 |
Not yet recruiting
New |
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients |
|
|
Interventional
|
Phase 1 |
- Nantes University Hospital
- Cyceron
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Detection of sensitivity of the lesions (osseous and extra-osseous) of 18Fludarabine PET (FludaTEP)
- To evaluate the specificity and the positive and negative predictive values of the FludaTEP for the initial assessment through an optimal reading mode.
- To evaluate the sensitivity, specificity, and positive and negative predictive values of the FludaTEP for the initial balance according to the local reading
- (and 4 more...)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT03832127 |
RC18_0055 |
Myelofludate |
April 1, 2019 |
April 1, 2022 |
April 1, 2024 |
February 6, 2019 |
February 6, 2019 |
|
- CHU d'Angers
Angers, France - CHU de Brest
Brest, France - CHU de Caen
Caen, France - (and 4 more...)
|
|
| 51 |
NCT01351545 |
Recruiting |
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
- Hematologic Malignancies
- Inherited Disorders of Metabolism
- Inherited Abnormalities of Platelets
- (and 14 more...)
|
- Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
|
Observational
|
|
- Center for International Blood and Marrow Transplant Research
- National Marrow Donor Program
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
|
99999 |
All |
Child, Adult, Older Adult |
NCT01351545 |
10-CBA |
|
October 2011 |
October 2021 |
|
May 11, 2011 |
February 15, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - (and 141 more...)
|
|
| 52 |
NCT03809780 |
Not yet recruiting
New |
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Kosin University Gospel Hospital
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
102 |
All |
up to 70 Years (Child, Adult, Older Adult) |
NCT03809780 |
LENDER |
LENDER |
February 1, 2019 |
December 1, 2023 |
December 3, 2024 |
January 18, 2019 |
January 18, 2019 |
|
- Kosin University Gospel Hospital
Busan, Western, Korea, Republic of
|
|
| 53 |
NCT03031730 |
Recruiting |
MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
- Hypercalcemia
- Plasmacytoma
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Drug: Carfilzomib
- Drug: Dexamethasone
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety parameters assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Incidence of treatment-emergent adverse event (TEAE) assessed by NCI CTCAE version 5.0
- Change in laboratory test results (hematology and blood chemistry)
- (and 13 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03031730 |
NCI-2017-00099
NCI10076
10076
UM1CA186688 |
|
October 27, 2017 |
March 31, 2019 |
March 31, 2019 |
January 26, 2017 |
February 12, 2019 |
|
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 54 |
NCT02791217 |
Not yet recruiting |
Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool |
- Lymphoma, B-Cell
- Follicular Lymphoma
- Hodgkin Lymphoma
- Multiple Myeloma
|
|
Observational
|
|
- Assuta Medical Center
- Laniado Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Molecular characteristics (by GEP, miRNA)
- Event free survival (EFS)
- Overall survival (OS)
|
100 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02791217 |
2015097 |
|
June 2016 |
June 2017 |
June 2019 |
June 6, 2016 |
June 6, 2016 |
|
|
|
| 55 |
NCT03122327 |
Not yet recruiting |
cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study. |
- Multiple Myeloma
- Comprehensive Geriatric Assessment
|
|
Observational
|
|
- Peking Union Medical College Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Current status of cGA in newly diagnosed elderly MM patients
- Association between the baseline cGA parameters and patients' overall survival
- Association between baseline cGA parameters and patients' progression free survival
|
200 |
All |
65 Years and older (Older Adult) |
NCT03122327 |
S-K230 |
|
May 1, 2017 |
May 1, 2020 |
May 1, 2022 |
April 20, 2017 |
April 25, 2017 |
|
|
|
| 56 |
NCT02129582 |
Recruiting |
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies |
- Acute Myeloid Leukemia
- Hematologic Malignancies
- Acute Lymphocytic Leukemia
- (and 8 more...)
|
- Radiation: total marrow irradiation
- Drug: fludarabine phosphate
- Drug: busulfan
- (and 5 more...)
|
Interventional
|
Phase 1 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of targeted marrow irradiation defined as the dose level immediately below that in which greater than or equal to 2/6 subjects experience a dose limiting toxicity assessed using NCI CTCAE version 4.0
- Incidence of toxicities assessed using NCI CTCAE version 4.0
- Patient mortality
- (and 6 more...)
|
78 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02129582 |
CASE9Z13
NCI-2014-00837
P30CA043703 |
|
June 6, 2014 |
March 2019 |
May 2019 |
May 2, 2014 |
December 14, 2018 |
|
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 57 |
NCT02566304 |
Recruiting |
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia in Remission
- Aplastic Anemia
- (and 12 more...)
|
- Drug: Fludarabine
- Radiation: Total-Body Irradiation
- Biological: T Cell-Depleted Donor Lymphocyte Infusion
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Relapse Related Mortality (RRM)
- Non-Relapse Mortality (NRM)
- (and 3 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02566304 |
15D.323
2015-054
NCI-2015-01506 |
|
November 13, 2015 |
April 23, 2020 |
January 2021 |
October 2, 2015 |
May 16, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 58 |
NCT03706547 |
Not yet recruiting |
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM |
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
|
- Biological: anti-CD19/BCMA CAR-T cells
- Drug: Fludarabine
- Drug: Cyclophosphamide
|
Interventional
|
Phase 1 |
- Peng Liu
- Hrain Biotechnology
- Shanghai East Hospital
- Shanghai Zhongshan Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0
- Overall remission rate defined by the standard response criteria for myeloma for each arm
- Duration of CAR-positive T cells in circulation
|
20 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03706547 |
SHZS-MM002 |
|
October 30, 2018 |
July 2020 |
December 2021 |
October 16, 2018 |
October 16, 2018 |
|
- Department of Hematology ,Fudan University Zhongshan Hospital
Shanghai, China
|
|
| 59 |
NCT03168438 |
Recruiting |
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma |
|
- Genetic: NY-ESO-1ᶜ²⁵⁹T cells
- Drug: NY-ESO-1ᶜ²⁵⁹T in combination with pembrolizumab
|
Interventional
|
Phase 2 |
- GlaxoSmithKline
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with Treatment Limiting Toxicities (TLT), adverse events (AE), including serious adverse events (SAE).
- Proportion of subjects with a positive response : Partial Response (PR), Very Good Partial response (VGPR), Complete Response (CR) or stringent CR (sCR)
- Interval between the date of T-cell infusion and first documented evidence of positive response (PR, VGPR, CR, sCR)
- (and 2 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03168438 |
208470
ADP-0011-008
KEYNOTE-487 |
|
August 18, 2017 |
April 19, 2021 |
April 19, 2021 |
May 30, 2017 |
October 4, 2018 |
|
- GSK Investigational Site
Duarte, California, United States - GSK Investigational Site
Tampa, Florida, United States - GSK Investigational Site
Baltimore, Maryland, United States
|
|
| 60 |
NCT02439112 |
Recruiting |
Exercise in Patients With Multiple Myeloma |
|
|
Interventional
|
Not Applicable |
- Zealand University Hospital
- Odense University Hospital
- Region Zealand
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in isometric knee extension strength measured by handhold dynamometer
- Change in lower limb strength measured by Sit-to-Stand Test
- Change in grip strength measured by hand dynamometer
- (and 7 more...)
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT02439112 |
Reum,fys/ergo 1 |
EMMY |
May 2015 |
December 31, 2019 |
December 31, 2019 |
May 8, 2015 |
July 6, 2018 |
|
- Odense University Hospital
Odense, Denmark - Zealand University Hospital
Roskilde, Denmark
|
|
| 61 |
NCT03543579 |
Recruiting |
Cardiovascular Complications of Carfilzomib Treatment |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Changes in endothelial function (Flow Mediated Dilatation in %) after drug administration
- Changes in carotid intima-media thickness (IMT)
- Changes in LV Ejection fraction
- Changes in systolic and diastolic strain and strain rate of LV
|
46 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT03543579 |
20168009 |
|
March 23, 2017 |
September 30, 2019 |
December 31, 2019 |
June 1, 2018 |
June 1, 2018 |
|
- Department of Clinical Therapeutics, "Alexandra" General Hospital
Athens, Greece
|
|
| 62 |
NCT02586038 |
Recruiting |
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS |
|
- Drug: MLN9708
- Drug: Dexamethasone
- Drug: Cyclophosphamide
- Drug: Thalidomide
|
Interventional
|
Phase 2 |
- Silvio Aime
- University of Turin, Italy
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Response rate
- Toxicity in terms of rate of hematologic and non-hematologic adverse events
- (and 4 more...)
|
183 |
All |
65 Years and older (Older Adult) |
NCT02586038 |
UNITO-EMN10 |
|
October 2015 |
October 2020 |
October 2023 |
October 26, 2015 |
February 19, 2018 |
|
- AO SS Antonio e Biagio e Cesare Arrigo di Alessandria
Alessandria, Italy
|
|
| 63 |
NCT03582033 |
Recruiting |
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants reporting one or more treatment-emergent adverse events (TEAEs)
- Number of participants with Grade 3 or higher adverse events (AEs)
- Number of participants reporting one or more serious adverse event (SAE)
- (and 11 more...)
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT03582033 |
SGNBCMA-001 |
|
November 1, 2018 |
September 2021 |
June 2022 |
July 10, 2018 |
February 4, 2019 |
|
- University of Miami
Miami, Florida, United States - Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 64 |
NCT03111992 |
Recruiting |
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma |
|
- Drug: PDR001
- Drug: CJM112
- Drug: LCL161
|
Interventional
|
Phase 1 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients reporting dose limiting toxicities
- The number of patients who experience a treatment-related adverse event after being treated with a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161
- The number of patients requiring interruptions after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161
- (and 12 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03111992 |
CPDR001X2106 |
|
December 18, 2017 |
May 27, 2020 |
May 27, 2020 |
April 13, 2017 |
January 21, 2019 |
|
- Novartis Investigative Site
Phoenix, Arizona, United States - Novartis Investigative Site
Nashville, Tennessee, United States - Novartis Investigative Site
Montreal, Quebec, Canada - (and 7 more...)
|
|
| 65 |
NCT03544281 |
Recruiting |
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
- Drug: GSK2857916
- Drug: Lenalidomide
- Drug: Dexamethasone
- (and 2 more...)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with AE's and serious adverse events (SAEs),Part 1
- Number of subjects with electrocardiogram (ECG) parameters of potential clinical importance (PCI), Part 1
- Number of subjects with abnormal hematology parameters, Part 1
- (and 69 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT03544281 |
207497 |
|
September 20, 2018 |
June 29, 2020 |
November 28, 2022 |
June 1, 2018 |
October 12, 2018 |
|
- GSK Investigational Site
Birmingham, Alabama, United States
|
|
| 66 |
NCT03383055 |
Recruiting |
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig |
|
- Biological: CMV-MVA Triplex Vaccine
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) between days 28 and 100 post-auto-HCT in patients with lymphoid malignancies.
- Change in absolute Number of CMV-induced adaptive NK Cells
- Response to CMV-MVA Triplex vaccine in CMV seropositive vs. seronegative patients
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03383055 |
2017LS091
MT2017-29 |
|
November 16, 2018 |
August 2020 |
August 2020 |
December 26, 2017 |
January 9, 2019 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 67 |
NCT03159702 |
Recruiting |
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation |
- Hematological Malignancy Undergoing a Related Donor Haploidentical HCT
- Leukemia
- Multiple Myeloma
- Lymphoma
|
- Drug: Evomela
- Drug: Fludarabine
- Radiation: Total Body Irradiation
|
Interventional
|
Phase 2 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The one-year progression-free survival (PFS) of patients with hematological malignancies undergoing treatment will be measured with exponential distribution and the Kaplan-Meier estimator.
- The safety of this trial will be evaluated with the nonreplapse mortality rate.
- Overall survival following reduced-intensity conditioning haploidentical transplantation will be calculated using the Kaplan-Meier estimator.
- (and 9 more...)
|
43 |
All |
18 Years and older (Adult, Older Adult) |
NCT03159702 |
PRO29507 |
|
December 8, 2017 |
July 1, 2020 |
July 1, 2023 |
May 19, 2017 |
July 13, 2018 |
|
- Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 68 |
NCT03272633 |
Not yet recruiting |
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies |
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia in Remission
- Hematopoietic Cell Transplantation Recipient
- (and 16 more...)
|
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Biological: Irradiated Allogeneic Cells
|
Interventional
|
Phase 2 |
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease response in patients who receive irradiated haploidentical cells (IHC)
- Incidence of toxicities associated with administration of irradiated haploidentical cells (IHC) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Induction of host T cells reactive with tumor associated epitopes
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03272633 |
011702
NCI-2017-01537
Pro20170000537
P30CA072720 |
|
February 1, 2019 |
April 30, 2020 |
April 30, 2020 |
September 5, 2017 |
December 18, 2018 |
|
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
|
|
| 69 |
NCT03385096 |
Not yet recruiting |
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT |
- Autologous Hematopoietic Stem Cell Transplantation
- Conditioning
- Multiple Myeloma
|
- Drug: Busulfan (BU)
- Drug: Cyclophosphamide (CY)
- Drug: Etoposide (VP-16)
- Drug: Melphalan
|
Interventional
|
Phase 2
Phase 3 |
- Nanfang Hospital of Southern Medical University
- Guangzhou First People's Hospital
- Zhujiang Hospital
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- OS
- relapse rate relapse rate
- DFS
- TRM
|
122 |
All |
14 Years to 65 Years (Child, Adult, Older Adult) |
NCT03385096 |
Mel vs BUCY+VP-16-MM-2017 |
|
January 2018 |
December 2020 |
December 2021 |
December 28, 2017 |
December 28, 2017 |
|
- Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
|
|
| 70 |
NCT03828292 |
Not yet recruiting
New |
An Open-label, Dose Escalation Study in Japanese Subjects With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with dose limiting toxicities (DLTs)
- Number of subjects with adverse events (AEs) and serious adverse events (SAEs)
- Number of subjects with abnormal hematology parameters
- (and 33 more...)
|
12 |
All |
20 Years and older (Adult, Older Adult) |
NCT03828292 |
207504 |
|
February 7, 2019 |
October 2, 2019 |
March 31, 2020 |
February 4, 2019 |
February 4, 2019 |
|
- GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Tokyo, Japan
|
|
| 71 |
NCT02134574 |
Recruiting |
Prospective Cohort With Hemopathy in Languedoc-Roussillon |
|
- Biological: hematologic malignancy
|
Observational
|
|
- University Hospital, Montpellier
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Survival with 2 years
- Survival with 5 years
- Survival with 10 years
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02134574 |
9011 |
DataDiag2012 |
February 2014 |
June 2033 |
June 2033 |
May 9, 2014 |
September 7, 2015 |
|
- Hematology department - UHMontpellier Saint éloi
Montpellier, France
|
|
| 72 |
NCT03192397 |
Recruiting |
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
- Acute Myeloid Leukemia in Remission
- Adult Acute Lymphoblastic Leukemia in Complete Remission
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
- (and 10 more...)
|
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: Fludarabine Phosphate
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Extensive chronic graft versus host disease (GVHD)
- Clinical response assessed as per bone marrow transplant (BMT) standard of care
- Cumulative incidence of grade III-IV acute graft versus host disease (GVHD)
- (and 5 more...)
|
30 |
All |
18 Years to 79 Years (Adult, Older Adult) |
NCT03192397 |
I 44417
NCI-2017-01069
P30CA016056 |
|
August 3, 2017 |
July 1, 2021 |
July 1, 2022 |
June 20, 2017 |
March 6, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 73 |
NCT00719888 |
Recruiting |
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease |
- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Acute Myeloid Leukemia in Remission
- (and 23 more...)
|
- Drug: Cyclophosphamide
- Drug: Cyclosporine
- Procedure: Double-Unit Umbilical Cord Blood Transplantation
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Incidence of transplant-related mortality
- Incidence of neutrophil engraftment
- (and 8 more...)
|
135 |
All |
6 Months to 45 Years (Child, Adult) |
NCT00719888 |
2010.00
NCI-2010-00190
FHCRC 2010.00
Protocol 2010
2010
P30CA015704
RG2807002 |
|
November 18, 2005 |
December 31, 2022 |
|
July 22, 2008 |
January 11, 2019 |
|
- University of Colorado Hospital
Aurora, Colorado, United States - VA Puget Sound Health Care System
Seattle, Washington, United States - Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 74 |
NCT03287908 |
Recruiting |
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma |
- Relapsed/Refractory Multiple Myeloma
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Subject incidence of adverse events as a Measure of Safety
- Subject incidence of dose-limiting toxicities (DLTs) as a Measure of Safety
- Anti-tumor activity
- Pharmacokinetic parameter of AMG 701
|
115 |
All |
18 Years and older (Adult, Older Adult) |
NCT03287908 |
20170122
2017-001997-41 |
|
November 13, 2017 |
July 23, 2020 |
August 6, 2023 |
September 19, 2017 |
February 1, 2019 |
|
- Research Site
Phoenix, Arizona, United States - Research Site
Little Rock, Arkansas, United States - Research Site
Jacksonville, Florida, United States - (and 17 more...)
|
|
| 75 |
NCT03489525 |
Recruiting |
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma |
- Relapsed/Refractory Multiple Myeloma
|
- Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
- Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of adverse events (AEs)
- Occurrence of SAE (serious adverse events)
- Occurrence of DLTs (dose limiting toxicities)
- (and 13 more...)
|
129 |
All |
18 Years to 101 Years (Adult, Older Adult) |
NCT03489525 |
D7900C00001 |
MEDI2228 |
May 8, 2018 |
April 23, 2021 |
April 23, 2021 |
April 5, 2018 |
January 21, 2019 |
|
- Research Site
Phoenix, Arizona, United States - Research Site
Jacksonville, Florida, United States - Research Site
Boston, Massachusetts, United States - (and 6 more...)
|
|
| 76 |
NCT01384513 |
Recruiting |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- (and 44 more...)
|
- Drug: Fludarabine
- Drug: Busulfan
- Radiation: Total Body Irradiation (TBI)
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS) in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemosensitive, indolent diseases
- Treatment Related Mortality (TRM)
- Incidence and severity of GVHD, graded according to standard criteria
- (and 5 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT01384513 |
11D.247
2011-31 |
|
August 4, 2011 |
December 1, 2019 |
July 2020 |
June 29, 2011 |
December 24, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 77 |
NCT03091127 |
Recruiting |
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Carfilzomib starting dose
- Carfilzomib dose
- Carfilzomib dose modification
- (and 47 more...)
|
800 |
All |
18 Years and older (Adult, Older Adult) |
NCT03091127 |
20150262 |
|
March 14, 2017 |
March 17, 2020 |
March 17, 2020 |
March 27, 2017 |
December 27, 2018 |
|
- Research Site
Braunau, Austria - Research Site
Innsbruck, Austria - Research Site
Leoben, Austria - (and 100 more...)
|
|
| 78 |
NCT03441958 |
Recruiting |
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma |
|
- Biological: ECT-001 (UM171) expanded cord blood
|
Interventional
|
Phase 1
Phase 2 |
- Ciusss de L'Est de l'Île de Montréal
- ExcellThera
- Centre de Commercialisation en Immunothérapie du Cancer (C3i)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of ECT-001 expanded CB expansion as measured by toxicity evaluation
- Feasibility of ECT-001 expanded CB expansion
- Measure of the kinetics of donor lymphoid cells recovery
- (and 28 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03441958 |
HMR007 |
|
March 7, 2018 |
March 1, 2022 |
March 1, 2024 |
February 22, 2018 |
March 12, 2018 |
|
- CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montréal, Quebec, Canada
|
|
| 79 |
NCT03687125 |
Recruiting |
Tinostamustine Conditioning and Autologous Stem Cell |
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
- Multiple Myeloma With Failed Remission
|
- Drug: Treatment with TINOSTAMUSTINE
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine objective response rate (ORR) based on the IMWG Response Criteria
- During the Phase 1 portion, determine dose limiting toxicities (DLT) according to CTCAE 4.03
- Objective response rate (ORR) for patients treated at the recommended phase 2 dose
- (and 6 more...)
|
71 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03687125 |
EDO-S101-1004
2018-001907-35 |
TITANIUM1 |
September 19, 2018 |
June 30, 2022 |
March 7, 2023 |
September 27, 2018 |
January 16, 2019 |
|
- University of Alabama
Birmingham, Alabama, United States - University of Kansas Medical Center Kansas City
Kansas City, Kansas, United States - Memorial Sloan Kettering Cancer Centre
New York, New York, United States - (and 9 more...)
|
|
| 80 |
NCT03246906 |
Recruiting |
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation |
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Aggressive Non-Hodgkin Lymphoma
- (and 14 more...)
|
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: Cyclosporine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Chronic graft versus host disease (GVHD)-free, relapse-free survival (CRFS)
- Grades II-IV and III-IV acute graft versus host disease (GVHD)
- Late graft versus host disease (GVHD) not meeting National Institute of Health (NIH) consensus criteria for chronic GVHD
- (and 5 more...)
|
160 |
All |
Child, Adult, Older Adult |
NCT03246906 |
9816
NCI-2017-01311
P01CA078902
P30CA015704 |
|
November 2, 2017 |
August 15, 2022 |
August 15, 2022 |
August 11, 2017 |
May 15, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 81 |
NCT02722668 |
Recruiting |
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
- Acute Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia/Lymphoma
- (and 22 more...)
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Drug: MMF
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Probability of Acute Graft Versus Host Disease (GVHD)
- Incidence of Acute GVHD
- Transplant related mortality
- (and 2 more...)
|
162 |
All |
up to 75 Years (Child, Adult, Older Adult) |
NCT02722668 |
2015LS149
MT2015-17 |
|
May 15, 2017 |
May 2028 |
December 2029 |
March 30, 2016 |
September 25, 2018 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 82 |
NCT03110562 |
Recruiting |
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma |
|
- Drug: Selinexor
- Drug: Bortezomib
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Karyopharm Therapeutics Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare progression-free survival (PFS) based on the Independent Review Committee's (IRC's) disease outcome assessments in patients randomized to the SVd Arm versus the Vd Arm
|
364 |
All |
18 Years and older (Adult, Older Adult) |
NCT03110562 |
KCP-330-023 |
BOSTON |
May 24, 2017 |
June 2020 |
June 2020 |
April 12, 2017 |
November 2, 2018 |
|
- Boca Raton Clinical Research (BRCR) Medical Center
Plantation, Florida, United States - Emory University
Atlanta, Georgia, United States - Kaiser Permanente Hawaii
Honolulu, Hawaii, United States - (and 162 more...)
|
|
| 83 |
NCT03136653 |
Recruiting |
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Biological: MP0250 plus BOR+DEX
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimate the efficacy of MP0250 plus BOR + DEX based on overall response rate (ORR)
- Determine the safety profile of MP0250 plus BOR + DEX
- Determine the immunogenicity of MP0250 plus BOR + DEX
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03136653 |
MP0250-CP201
2016-002771-10 |
|
May 23, 2017 |
October 2019 |
December 2019 |
May 2, 2017 |
August 16, 2018 |
|
- University of Essen, Haematology
Essen, Germany - University of Heidelberg, Haematology, Oncology
Heidelberg, Germany - University of Würzburg, Haematology, Oncology
Würzburg, Germany - (and 6 more...)
|
|
| 84 |
NCT02004275 |
Recruiting |
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Drug: pomalidomide
- Drug: ixazomib
- Drug: dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Celgene Corporation
- Millennium Pharmaceuticals, Inc.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of pomalidomide and ixazomib, determined according to incidence of dose limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
- Progression free survival (PFS) (Phase II)
- Incidence and type of dose limiting toxicities (DLTs), serious adverse events, and adverse events, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
- (and 11 more...)
|
73 |
All |
18 Years and older (Adult, Older Adult) |
NCT02004275 |
A061202
NCI-2013-01702
U10CA031946 |
|
February 2014 |
March 2021 |
|
December 9, 2013 |
January 24, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 324 more...)
|
|
| 85 |
NCT02188368 |
Recruiting |
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients |
|
- Drug: POM
- Drug: Steroids
- Drug: PLD
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Oncotherapeutics
- Celgene Corporation
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Number of subjects with adverse events
- Overall Response Rate
- (and 6 more...)
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT02188368 |
PO-CL-MM-PI-003854 |
|
August 2014 |
December 2018 |
December 2018 |
July 11, 2014 |
October 5, 2018 |
|
- California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, United States - Compassionate Care Research Group
Fountain Valley, California, United States - Comprehensive Cancer Center at Desert Regional Medical Center
Palm Springs, California, United States - (and 9 more...)
|
|
| 86 |
NCT02761187 |
Recruiting |
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of Participants with Co-morbidities
- Number of Participants Diagnosed with ND MM and R/R MM
- Number of Participants Presenting Symptoms of ND MM and R/R MM
- (and 22 more...)
|
4200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02761187 |
NSMM-5001 |
|
July 1, 2016 |
July 1, 2024 |
July 1, 2024 |
May 4, 2016 |
January 9, 2019 |
|
- CARTI Cancer Center
Little Rock, Arkansas, United States - University of Arkansas For Medical Sciences
Little Rock, Arkansas, United States - University of California San Diego
La Jolla, California, United States - (and 134 more...)
|
|
| 87 |
NCT03277105 |
Recruiting |
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Dara SC
- Drug: Dara IV
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Maximum Trough Concentration (Ctrough) of Daratumumab
- Percentage of participants With Infusion-Related Reactions (IRR)
- (and 8 more...)
|
480 |
All |
18 Years and older (Adult, Older Adult) |
NCT03277105 |
CR108342
2017-000206-38
54767414MMY3012 |
|
October 27, 2017 |
November 5, 2019 |
October 8, 2020 |
September 8, 2017 |
February 8, 2019 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Washington University
Saint Louis, Missouri, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - (and 162 more...)
|
|
| 88 |
NCT02654990 |
Recruiting |
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma |
|
- Drug: panobinostat capsules
- Drug: bortezomib injection
- Drug: dexamethasone tablets
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) up to 8 cycles
- ORR throughout study
- individual immunophenotypic complete response (CR) rate
- (and 14 more...)
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT02654990 |
CLBH589D2222 |
PANORAMA_3 |
April 27, 2016 |
June 10, 2019 |
December 15, 2022 |
January 13, 2016 |
February 15, 2019 |
|
- Highlands Oncology Group
Fayetteville, Arkansas, United States - Los Angeles Hematology/Oncology Medical Group Wilson Terr
Los Angeles, California, United States - Poudre Valley Hospital SC
Fort Collins, Colorado, United States - (and 90 more...)
|
|
| 89 |
NCT03652064 |
Recruiting |
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy |
|
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Negative Minimal Residual Disease (MRD) Status
- Progression-Free Survival (PFS)
- MRD Negative Rate at 1 Year
- (and 14 more...)
|
360 |
All |
18 Years and older (Adult, Older Adult) |
NCT03652064 |
CR108529
2018-001545-13
54767414MMY3019 |
|
November 6, 2018 |
March 29, 2024 |
April 30, 2025 |
August 29, 2018 |
February 8, 2019 |
|
- Sharp Center for Research
San Diego, California, United States - Innovative Clinical Research, Inc.
Whittier, California, United States - Baptist MD Anderson
Jacksonville, Florida, United States - (and 122 more...)
|
|
| 90 |
NCT01768845 |
Recruiting |
Unrelated Umbilical Cord Blood (UBC)Transplantation |
- Chronic Myelogenous Leukemia (CML)
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome
- (and 6 more...)
|
- Genetic: umbilical cord blood (UCB)
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Engraftment
- Overall survival
|
40 |
All |
16 Years to 70 Years (Child, Adult, Older Adult) |
NCT01768845 |
WVU 1909 |
|
February 2009 |
December 2019 |
December 2019 |
January 15, 2013 |
May 28, 2018 |
|
- West Virginia University Hospitals Mary Babb Randolph Cancer Center
Morgantown, West Virginia, United States
|
|
| 91 |
NCT03301220 |
Recruiting |
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma |
- Smoldering Multiple Myeloma
|
- Drug: Daratumumab SC: daratumumab + rHuPH20
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS)
- Time to Biochemical or Diagnostic (SLiM-CRAB) Progression
- Overall Response Rate (ORR)
- (and 15 more...)
|
360 |
All |
18 Years and older (Adult, Older Adult) |
NCT03301220 |
CR108172
54767414SMM3001
2016-001205-16 |
|
November 7, 2017 |
December 16, 2021 |
December 22, 2025 |
October 4, 2017 |
February 8, 2019 |
|
- Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States - UCLA
Santa Monica, California, United States - Innovative Clinical Research, Inc.
Whittier, California, United States - (and 183 more...)
|
|
| 92 |
NCT01863550 |
Recruiting |
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Bortezomib
- Drug: Carfilzomib
- Drug: Dexamethasone
- (and 3 more...)
|
Interventional
|
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) for the maintenance analysis
- Progression-free survival for the induction analysis
- Progression-free survival for the maintenance analysis
- (and 16 more...)
|
1080 |
All |
18 Years and older (Adult, Older Adult) |
NCT01863550 |
E1A11
NCI-2012-02608
ECOG-E1A11
s17-00040
U10CA180820
U10CA021115
U24CA196172 |
|
December 2, 2013 |
November 1, 2023 |
|
May 29, 2013 |
August 22, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 917 more...)
|
|
| 93 |
NCT03173092 |
Recruiting |
An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) |
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 4 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Percentage of Participants with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR)
- Duration of Response
- (and 3 more...)
|
160 |
All |
18 Years and older (Adult, Older Adult) |
NCT03173092 |
C16038
U1111-1192-7696 |
|
September 20, 2017 |
November 30, 2023 |
November 30, 2023 |
June 1, 2017 |
February 6, 2019 |
|
- Arizona Oncology Associates, P.C.
Tucson, Arizona, United States - CARTI Cancer Center
Little Rock, Arkansas, United States - Pacific Cancer Medical Center
Anaheim, California, United States - (and 25 more...)
|
|
| 94 |
NCT03244930 |
Recruiting |
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation |
- Lymphoma, Non-Hodgkin
- Lymphoma, Hodgkin
- Myeloma
- Stem Cell Transplant Complications
|
- Drug: Plerixafor 0.12 mg/kg
|
Interventional
|
Phase 2 |
- Hospital Universitario Dr. Jose E. Gonzalez
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Harvest of of at least 2 x106 CD34+/kg
- Time to engraftment
- Rate of patients reaching a peripheral blood precount higher than 20 cells/μL
|
20 |
All |
Child, Adult, Older Adult |
NCT03244930 |
HE17-00007 |
|
May 10, 2017 |
May 10, 2018 |
June 10, 2018 |
August 10, 2017 |
August 10, 2017 |
|
- Servicio de Hematología Hospital Universitario "Dr. José Eleuterio Gonzalez", Universidad Autónoma de Nuevo Leon
Monterrey, Nuevo Leon, Mexico
|
|
| 95 |
NCT02661035 |
Recruiting |
Allo HSCT Using RIC for Hematological Diseases |
- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- (and 15 more...)
|
- Drug: Allopurinol
- Drug: Fludarabine
- Drug: Cyclophosphamide
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate rates of acute graft-versus-host disease (GVHD) II-IV
- Evaluate rates of chronic GVHD
- Evaluate neutrophil engraftment without ATG (in siblings)
- (and 10 more...)
|
124 |
All |
up to 75 Years (Child, Adult, Older Adult) |
NCT02661035 |
2015LS152 |
|
March 9, 2017 |
March 2023 |
March 2023 |
January 21, 2016 |
September 25, 2018 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 96 |
NCT03170882 |
Recruiting |
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma |
- Relapsed and/or Refractory Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2
Phase 3 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Percentage of Participants with Objective Response Rate (ORR - Partial Response [PR], Very Good Partial Response [VGPR] and Complete Response [CR])
- (and 9 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03170882 |
C16029
2016-004742-28
U1111-1188-2677
2017/1235
N-20170083
17/NW/0546 |
|
July 25, 2017 |
November 30, 2021 |
March 31, 2023 |
May 31, 2017 |
February 12, 2019 |
|
- Highlands Oncology Group
Fayetteville, Arkansas, United States - St Joseph Heritage Healthcare
Santa Rosa, California, United States - Lynn Cancer Institute
Boca Raton, Florida, United States - (and 121 more...)
|
|
| 97 |
NCT01951885 |
Recruiting |
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention |
- Chronic Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- (and 7 more...)
|
- Drug: tacrolimus
- Drug: methotrexate
- Drug: Mycophenolate mofetil
- Drug: Methotrexate (low dose)
|
Interventional
|
Phase 3 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Incidence of severe (grade 3-4) mucositis graded according to the World Health Organization (WHO) grading scale
- Time to neutrophil engraftment
- Time to platelet engraftment
- (and 11 more...)
|
100 |
All |
up to 70 Years (Child, Adult, Older Adult) |
NCT01951885 |
CASE6Z13
NCI-2013-01800
CASE 6Z13
P30CA043703 |
|
May 21, 2014 |
May 2019 |
July 2019 |
September 27, 2013 |
January 3, 2019 |
|
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States - Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 98 |
NCT02963493 |
Recruiting |
A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients |
|
- Drug: Melflufen
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Oncopeptides AB
- Precision Oncology
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Progression Free Survival (PFS)
- Duration of Response
- (and 3 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT02963493 |
OP-106 |
HORIZON |
December 2016 |
March 2020 |
November 2021 |
November 15, 2016 |
November 27, 2018 |
|
- Innovative Clinical Research Institute (ICRI)
Whittier, California, United States - University of Florida
Gainesville, Florida, United States - RUSH
Chicago, Illinois, United States - (and 15 more...)
|
|
| 99 |
NCT02294357 |
Recruiting |
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib |
|
- Drug: Carfilzomib
- Drug: Dexamethasone
- Drug: Prednisone
- (and 3 more...)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Clinical Benefit Rate (CBR)
- Number of patients undergoing adverse events
- (and 5 more...)
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT02294357 |
IST-CAR-2014-100701 (20159897) |
|
December 2014 |
November 2018 |
December 2018 |
November 19, 2014 |
October 5, 2018 |
|
- California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, United States - Wellness Oncology and Hematology
West Hills, California, United States - James R Berenson, MD, Inc.
West Hollywood, California, United States - (and 4 more...)
|
|
| 100 |
NCT02519452 |
Recruiting |
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Daratumumab Subcutaneous (SC) Administration
- Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
|
Interventional
|
Phase 1 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Trough Concentrations (Ctrough) of Daratumumab
- Part 1, 2 and 3: Number of Participants with Adverse Events (AEs) and Serious AEs
- Part 1, 2 and 3: Serum Concentration of Daratumumab and Recombinant Human Hyaluronidase (rHuPH20) (Plasma) Antibodies
- (and 4 more...)
|
108 |
All |
18 Years and older (Adult, Older Adult) |
NCT02519452 |
CR107838
2015-001210-94
54767414MMY1004 |
|
October 22, 2015 |
December 13, 2017 |
June 17, 2021 |
August 11, 2015 |
February 4, 2019 |
|
- Winship Cancer Institute Emory University
Atlanta, Georgia, United States - Mt. Sinai School of Medicine
New York, New York, United States - Levine Cancer Institute
Charlotte, North Carolina, United States - (and 12 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: